## Françoise Van Bambeke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2419733/publications.pdf

Version: 2024-02-01

222 papers 9,665 citations

54 h-index <sup>53230</sup> **85** 

g-index

226 all docs 226 docs citations

times ranked

226

10473 citing authors

#	Article	IF	Citations
1	Hydrolytic Enzymes as Potentiators of Antimicrobials against an Inter-Kingdom Biofilm Model. Microbiology Spectrum, 2022, 10, e0258921.	3.0	5
2	Host Cell Oxidative Stress Induces Dormant Staphylococcus aureus Persisters. Microbiology Spectrum, 2022, 10, e0231321.	3.0	24
3	Pharmacodynamics of Moxifloxacin, Meropenem, Caspofungin, and Their Combinations against <i>In Vitro</i> Polymicrobial Interkingdom Biofilms. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0214921.	3.2	4
4	Role of Efflux in Antibiotic Resistance of Achromobacter xylosoxidans and Achromobacter insuavis Isolates From Patients With Cystic Fibrosis. Frontiers in Microbiology, 2022, 13, 762307.	3 <b>.</b> 5	9
5	Antibiotic Usage in Patients Having Undergone Caesarean Section: A Three-Level Study in Benin. Antibiotics, 2022, 11, 617.	3.7	5
6	The polyamino-isoprenyl potentiator NV716 revives disused antibiotics against Gram-negative bacteria in broth, infected monocytes, or biofilms, by disturbing the barrier effect of their outer membrane. European Journal of Medicinal Chemistry, 2022, 238, 114496.	5 <b>.</b> 5	5
7	Healthcare Professionals' Knowledge and Beliefs on Antibiotic Prophylaxis in Cesarean Section: A Mixed-Methods Study in Benin. Antibiotics, 2022, 11, 872.	3.7	2
8	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. Antibiotics, 2022, 11, 898.	3.7	4
9	The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	9
10	First detection of a plasmid-encoded New-Delhi metallo-beta-lactamase-1 (NDM-1) producing Acinetobacter baumannii using whole genome sequencing, isolated in a clinical setting in Benin. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 5.	3.8	6
11	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. Methods in Molecular Biology, 2021, 2357, 239-251.	0.9	2
12	<i>In Vitro</i> Study of the Synergistic Effect of an Enzyme Cocktail and Antibiotics against Biofilms in a Prosthetic Joint Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
13	Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Pharmaceutics, 2021, 13, 456.	4.5	1
14	Antimicrobial potentials of essential oils extracted from West African aromatic plants on common skin infections. Scientific African, 2021, 11, e00706.	1.5	6
15	Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers. Antibiotics, 2021, 10, 530.	3.7	20
16	<i>In vitro</i> polymicrobial inter-kingdom three-species biofilm model: influence of hyphae on biofilm formation and bacterial physiology. Biofouling, 2021, 37, 481-493.	2.2	5
17	Intracellular Activity of Antibiotics against Coxiella burnetii in a Model of Activated Human THP-1 Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, e0106121.	3.2	7
18	Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an <i>In Vitro</i> Model of Intracellular Infection. Antimicrobial Agents and Chemotherapy, 2021, 65, e0146821.	3.2	7

#	Article	IF	Citations
19	Activity of Moxifloxacin Against Biofilms Formed by Clinical Isolates of Staphylococcus aureus Differing by Their Resistant or Persister Character to Fluoroquinolones. Frontiers in Microbiology, 2021, 12, 785573.	3.5	5
20	Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe. International Journal of Antimicrobial Agents, 2020, 55, 105825.	2.5	7
21	Antibiotic Resistance, Biofilm Formation, and Intracellular Survival As Possible Determinants of Persistent or Recurrent Infections by Staphylococcus aureus in a Vietnamese Tertiary Hospital: Focus on Bacterial Response to Moxifloxacin. Microbial Drug Resistance, 2020, 26, 537-544.	2.0	16
22	Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes. Clinical Microbiology and Infection, 2020, 26, 1254.e1-1254.e8.	6.0	14
23	Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells. International Journal of Antimicrobial Agents, 2020, 55, 105848.	2.5	6
24	Synergistic Effects of Pulsed Lavage and Antimicrobial Therapy Against Staphylococcus aureus Biofilms in an in-vitro Model. Frontiers in Medicine, 2020, 7, 527.	2.6	8
25	Antimicrobial resistance in hospitalized surgical patients: a silently emerging public health concern in Benin. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 54.	3.8	9
26	4CPS-031â€Audit of antibiotic prophylaxis practice in visceral surgery in an African country. , 2020, , .		1
27	Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoeaâ€"challenges and opportunities. Clinical Microbiology and Infection, 2020, 26, 1630-1635.	6.0	16
28	The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin. Frontiers in Microbiology, 2020, 11, 587364.	3.5	11
29	Intracellular Staphylococcus aureus persisters upon antibiotic exposure. Nature Communications, 2020, 11, 2200.	12.8	197
30	Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 2650-2656.	3.0	9
31	Increased Azithromycin Susceptibility of Multidrug-Resistant Gram-Negative Bacteria on RPMI-1640 Agar Assessed by Disk Diffusion Testing. Antibiotics, 2020, 9, 218.	3.7	17
32	Activity of Antibiotics against Pseudomonas aeruginosa in an <i>In Vitro</i> Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	18
33	Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio. European Journal of Medicinal Chemistry, 2020, 200, 112444.	5 <b>.</b> 5	20
34	Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials. American Journal of Tropical Medicine and Hygiene, 2020, 103, 960-964.	1.4	34
35	Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines. International Journal of Antimicrobial Agents, 2019, 54, 661-667.	2.5	3
36	Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes. International Journal of Antimicrobial Agents, 2019, 54, 702-708.	2.5	16

#	Article	IF	CITATIONS
37	Activity of Antibiotics against Staphylococcus aureus in an <i>In Vitro</i> Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20
38	Profile of a Novel Anionic Fluoroquinolone—Delafloxacin. Clinical Infectious Diseases, 2019, 68, S213-S222.	5.8	44
39	Investigation of unbound colistin A and B in clinical samples using a mass spectrometry method. International Journal of Antimicrobial Agents, 2019, 53, 330-336.	2.5	3
40	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. Journal of Antimicrobial Chemotherapy, 2019, 74, 1459-1461.	3.0	2
41	Natural and hemi-synthetic pentacyclic triterpenes as antimicrobials and resistance modifying agents against Staphylococcus aureus: a review. Phytochemistry Reviews, 2018, 17, 1129-1163.	6.5	52
42	Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?. Clinical Microbiology and Infection, 2018, 24, 570-572.	6.0	54
43	Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	14
44	Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism,) Tj ETQq0 0 0 rg	gBT /Overl	ock 10 Tf 50 4 21
45	Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in <i>In Vitro</i> Static and Dynamic Models. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
46	Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. Journal of Antimicrobial Chemotherapy, 2018, 73, 1630-1638.	3.0	4
47	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio. European Journal of Medicinal Chemistry, 2018, 159, 324-338.	5.5	20
48	Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient. PLoS ONE, 2018, 13, e0204167.	2.5	24
49	Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. International Journal of Antimicrobial Agents, 2018, 52, 697-701.	2.5	47
50	Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies. Journal of Antimicrobial Chemotherapy, 2018, 73, 2806-2814.	3.0	23
51	The Putative De-N-acetylase DnpA Contributes to Intracellular and Biofilm-Associated Persistence of Pseudomonas aeruginosa Exposed to Fluoroquinolones. Frontiers in Microbiology, 2018, 9, 1455.	3.5	6
52	Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Scientific Reports, 2017, 7, 40208.	3.3	34
53	Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	33
54	Acquired resistance to macrolides in <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. European Respiratory Journal, 2017, 49, 1601847.	6.7	42

#	Article	IF	CITATIONS
55	Optimizing $\hat{l}^2$ -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. Expert Review of Anti-Infective Therapy, 2017, 15, 677-688.	4.4	77
56	Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of <i>Pseudomonas aeruginosa </i> . Journal of Antimicrobial Chemotherapy, 2017, 72, dkw587.	3.0	5
57	Determining $\hat{I}^2$ -lactam exposure threshold to suppress resistance development in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2017, 72, 1421-1428.	3.0	72
58	Mechanisms of Action. , 2017, , 1162-1180.e1.		30
59	Synergy between Ursolic and Oleanolic Acids from Vitellaria paradoxa Leaf Extract and $\hat{l}^2$ -Lactams against Methicillin-Resistant Staphylococcus aureus: In Vitro and In Vivo Activity and Underlying Mechanisms. Molecules, 2017, 22, 2245.	3.8	34
60	Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models. Frontiers in Microbiology, 2017, 8, 2585.	3.5	9
61	Synergistic activity between an antimicrobial polyacrylamide and daptomycin versusStaphylococcus aureusbiofilm. Pathogens and Disease, 2016, 74, ftw042.	2.0	10
62	Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe. Antimicrobial Agents and Chemotherapy, 2016, 60, 6735-6741.	3.2	43
63	Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs <i>Pseudomonas aeruginosa </i> Pathogenicity and Inflammasome Activation. Journal of Infectious Diseases, 2016, 214, 1105-1116.	4.0	26
64	The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. Nature Communications, 2016, 7, 13286.	12.8	41
65	High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. International Journal of Antimicrobial Agents, 2016, 48, 740-743.	2.5	55
66	Modulating antibiotic activity towards respiratory bacterial pathogens by co-medications: a multi-target approach. Drug Discovery Today, 2016, 21, 1114-1129.	6.4	12
67	Targeting the Type Three Secretion System in Pseudomonas aeruginosa. Trends in Pharmacological Sciences, 2016, 37, 734-749.	8.7	97
68	The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2016, 14, 311-324.	4.4	17
69	<i>Editorial Commentary</i> : Colistin and a New Paradigm in Drug Development. Clinical Infectious Diseases, 2016, 62, 559-560.	5.8	3
70	Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia. International Journal of Antimicrobial Agents, 2016, 47, 77-83.	2.5	20
71	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. Methods in Molecular Biology, 2016, 1333, 147-157.	0.9	12
72	Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014). PLoS ONE, 2016, 11, e0154816.	2.5	11

#	Article	IF	CITATIONS
73	Preliminary evidences of the direct and indirect antimicrobial activity of 12 plants used in traditional medicine in Africa. Phytochemistry Reviews, 2015, 14, 975-991.	6.5	8
74	Activities of Antibiotic Combinations against Resistant Strains of Pseudomonas aeruginosa in a Model of Infected THP-1 Monocytes. Antimicrobial Agents and Chemotherapy, 2015, 59, 258-268.	3.2	17
75	Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. International Journal of Antimicrobial Agents, 2015, 46, 660-665.	2.5	5
76	Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1596-1598.	3.0	27
77	Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms. Journal of Antimicrobial Chemotherapy, 2015, 70, 1713-26.	3.0	4
78	Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. Clinical Biochemistry, 2015, 48, 542-545.	1.9	12
79	RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 4750-4758.	3.2	1
80	Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiology, 2015, 10, 1111-1123.	2.0	63
81	Reviving old antibiotics. Journal of Antimicrobial Chemotherapy, 2015, 70, 2177-2181.	3.0	79
82	Correlation between cytotoxicity induced by <i>Pseudomonas aeruginosa </i> clinical isolates from acute infections and IL- $1\hat{1}^2$ secretion in a model of human THP-1 monocytes. Pathogens and Disease, 2015, 73, ftv049.	2.0	16
83	Cellular Pharmacokinetics and Intracellular Activity of the Novel Peptide Deformylase Inhibitor GSK1322322 against Staphylococcus aureus Laboratory and Clinical Strains with Various Resistance Phenotypes: Studies with Human THP-1 Monocytes and J774 Murine Macrophages. Antimicrobial Agents and Chemotherapy, 2015, 59, 5747-5760.	3.2	16
84	Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review. Drugs, 2015, 75, 2073-2095.	10.9	61
85	Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. Journal of Antimicrobial Chemotherapy, 2015, 70, 207-216.	3.0	55
86	Antibiotic Activity against Naive and Induced Streptococcus pneumoniae Biofilms in an <i>In Vitro</i> Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 1348-1358.	3.2	18
87	Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones. Annals of Medicine, 2014, 46, 512-529.	3.8	28
88	Study of Macrophage Functions in Murine J774 Cells and Human Activated THP-1 Cells Exposed to Oritavancin, a Lipoglycopeptide with High Cellular Accumulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 2059-2066.	3.2	19
89	Macrolides and Ketolides. , 2014, , 257-278.		3
90	Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. Journal of Pharmaceutical and Biomedical Analysis, 2014, 90, 192-197.	2.8	11

#	Article	IF	Citations
91	Characterisation of a collection of Streptococcus pneumoniae isolates from patients suffering from acute exacerbations of chronic bronchitis: In vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups. International Journal of Antimicrobial Agents, 2014, 44, 209-217.	2.5	10
92	Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus aureus Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 6385-6397.	3.2	88
93	New Amphiphilic Neamine Derivatives Active against Resistant Pseudomonas aeruginosa and Their Interactions with Lipopolysaccharides. Antimicrobial Agents and Chemotherapy, 2014, 58, 4420-4430.	3.2	52
94	Pharmacological Characterization of 7-(4-(Piperazin-1-yl)) Ciprofloxacin Derivatives: Antibacterial Activity, Cellular Accumulation, Susceptibility to Efflux Transporters, and Intracellular Activity. Pharmaceutical Research, 2014, 31, 1290-1301.	3.5	20
95	2-Aminobenzothiazole derivatives: Search for new antifungal agents. European Journal of Medicinal Chemistry, 2013, 64, 357-364.	5.5	75
96	Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. Journal of Antimicrobial Chemotherapy, 2013, 68, 1455-1464.	3.0	154
97	Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. Journal of Antimicrobial Chemotherapy, 2013, 68, 648-658.	3.0	16
98	A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus aureus Biofilms. Antimicrobial Agents and Chemotherapy, 2013, 57, 2726-2737.	3.2	114
99	Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards Pseudomonas aeruginosa PAO1 in a Model of THP-1 Human Monocytes. Antimicrobial Agents and Chemotherapy, 2013, 57, 2310-2318.	3.2	49
100	Analysis of the Membrane Proteome of Ciprofloxacin-Resistant Macrophages by Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC). PLoS ONE, 2013, 8, e58285.	2.5	8
101	Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability. Clinical Infectious Diseases, 2012, 55, 534-542.	5.8	90
102	Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin. Clinical Infectious Diseases, 2012, 54, S229-S232.	5.8	21
103	Influence of the Protein Kinase C Activator Phorbol Myristate Acetate on the Intracellular Activity of Antibiotics against Hemin- and Menadione-Auxotrophic Small-Colony Variant Mutants of Staphylococcus aureus and Their Wild-Type Parental Strain in Human THP-1 Cells. Antimicrobial Agents and Chemotherapy, 2012, 56, 6166-6174.	3.2	13
104	Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 771-775.	3.0	16
105	Pharmacodynamic Evaluation of the Activity of Antibiotics against Hemin- and Menadione-Dependent Small-Colony Variants of Staphylococcus aureus in Models of Extracellular (Broth) and Intracellular (THP-1 Monocytes) Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 3700-3711.	3.2	36
106	Intracellular forms of menadione-dependent small-colony variants of methicillin-resistant Staphylococcus aureus are hypersusceptible to Â-lactams in a THP-1 cell model due to cooperation between vacuolar acidic pH and oxidant species. Journal of Antimicrobial Chemotherapy, 2012, 67, 2873-2881.	3.0	15
107	Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin. Journal of Antimicrobial Chemotherapy, 2012, 67, 2158-2164.	3.0	30
108	Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. International Journal of Antimicrobial Agents, 2012, 39, 208-216.	2.5	8

#	Article	IF	CITATIONS
109	Activity of Fusidic Acid Against Extracellular and Intracellular Staphylococcus aureus: Influence of pH and Comparison With Linezolid and Clindamycin. Clinical Infectious Diseases, 2011, 52, S493-S503.	5.8	31
110	Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. International Journal of Antimicrobial Agents, 2011, 38, 52-59.	2.5	52
111	Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. International Journal of Antimicrobial Agents, 2011, 38, 249-56.	2.5	34
112	Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against <i>Staphylococcus aureus</i> . Antimicrobial Agents and Chemotherapy, 2011, 55, 649-658.	3.2	160
113	Editorial [Hot Topic: ABC Transporters: Role in Modulation of Drug Pharmacokinetics and in Physiopathology and Therapeutic Perspectives (Guest Editor: Francoise Van Bambeke)]. Current Drug Targets, 2011, 12, 598-599.	2.1	O
114	Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. Toxicology, 2011, 290, 178-186.	4.2	9
115	Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. Free Radical Biology and Medicine, 2011, 51, 1656-1665.	2.9	91
116	Intra- and Extracellular Activities of Dicloxacillin and Linezolid against a ClinicalStaphylococcus aureusStrain with a Small-Colony-Variant Phenotype in anIn VitroModel of THP-1 Macrophages and anIn VivoMouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1443-1452.	3.2	19
117	Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 2011, 66, 1414-1415.	3.0	O
118	Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. Journal of Antimicrobial Chemotherapy, 2011, 66, 596-607.	3.0	32
119	Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 948-951.	3.0	3
120	ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions. Current Drug Targets, 2011, 12, 600-620.	2.1	141
121	Characterization of Abcc4 Gene Amplification in Stepwise-Selected Mouse J774 Macrophages Resistant to the Topoisomerase II Inhibitor Ciprofloxacin. PLoS ONE, 2011, 6, e28368.	2.5	12
122	Cellular Pharmacokinetics of the Novel Biaryloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils. Antimicrobial Agents and Chemotherapy, 2010, 54, 2540-2548.	3.2	73
123	Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. Journal of Antimicrobial Chemotherapy, 2010, 65, 1228-1236.	3.0	15
124	Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. Journal of Antimicrobial Chemotherapy, 2010, 65, 1720-1724.	3.0	41
125	Cellular Pharmacodynamics of the Novel Biaryloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, Using <i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Listeria monocytogenes</i> , and <i>Legionella pneumophila</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 2549-2559.	3.2	58
126	Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. Journal of Antimicrobial Chemotherapy, 2010, 65, 962-973.	3.0	24

#	Article	IF	Citations
127	Intra- and Extracellular Activities of Dicloxacillin against <i>Staphylococcus aureus In Vivo</i> and <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 2391-2400.	3.2	21
128	In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. International Journal of Antimicrobial Agents, 2010, 36, 513-522.	2.5	72
129	Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 2010, 65, 2076-2082.	3.0	50
130	Dynamics and Structural Changes Induced by ATP Binding in SAV1866, a Bacterial ABC Exporter. Journal of Physical Chemistry B, 2010, 114, 15948-15957.	2.6	43
131	Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1876-1885.	2.6	26
132	Mechanisms of action., 2010, , 1288-1307.		0
133	Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. Journal of Antimicrobial Chemotherapy, 2009, 64, 1035-1043.	3.0	59
134	Plectasin Shows Intracellular Activity against <i>Staphylococcus aureus</i> in Human THP-1 Monocytes and in a Mouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 4801-4808.	3.2	59
135	Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1) Tj ETQq1 1 Methicillin-Resistant <i>Staphylococcus aureus</i> i>. Antimicrobial Agents and Chemotherapy, 2009, 53, 2289-2297.	0.784314 ı 3.2	rgBT /Overlock 1 41
136	Identification of the Efflux Transporter of the Fluoroquinolone Antibiotic Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells. Antimicrobial Agents and Chemotherapy, 2009, 53, 2410-2416.	3.2	26
137	DD-Ligases as a Potential Target for Antibiotics: Past, Present and Future. Current Medicinal Chemistry, 2009, 16, 2566-2580.	2.4	27
138	Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against <i>Staphylococcus aureus</i> , <i>Listeria monocytogenes</i> , and <i>Legionella pneumophila</i> in Human THP-1 Macrophages. Antimicrobial Agents and Chemotherapy, 2009, 53, 3734-3743.	3.2	53
139	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations. Antimicrobial Agents and Chemotherapy, 2009, 53, 1443-1449.	3.2	37
140	Role of <i>rsbU</i> and Staphyloxanthin in Phagocytosis and Intracellular Growth of <i>Staphylococcus aureus</i> in Human Macrophages and Endothelial Cells. Journal of Infectious Diseases, 2009, 200, 1367-1370.	4.0	39
141	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a <i>Staphylococcus aureus</i> Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains. Antimicrobial Agents and Chemotherapy, 2009, 53, 1434-1442.	3.2	54
142	Synthesis and Biological Evaluation of 2â€Mercaptoâ€1,3â€benzothiazole Derivatives with Potential Antimicrobial Activity. Archiv Der Pharmazie, 2009, 342, 605-613.	4.1	66
143	Isolation and 2â€Dâ€DIGE proteomic analysis of intracellular and extracellular forms of <i>Listeria monocytogenes</i> . Proteomics, 2009, 9, 5484-5496.	2.2	18
144	Structureâ€Based Design of Benzoxazoles as new Inhibitors for Dâ€Alanyl – Dâ€Alanine Ligase. QSAR and Combinatorial Science, 2009, 28, 1394-1404.	1.4	10

#	Article	IF	CITATIONS
145	Molecular models of human P-glycoprotein in two different catalytic states. BMC Structural Biology, 2009, 9, 3.	2.3	63
146	Penicillin-binding Proteins (PBP) and Lmo0441 (a PBP-like protein) play a role in Beta-lactam sensitivity of Listeria monocytogenes. Gut Pathogens, 2009, 1, 23.	3.4	10
147	Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 1832-1840.	2.6	77
148	Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin. Drug Safety, 2009, 32, 359-378.	3.2	108
149	Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clinical Microbiology and Infection, 2008, 14, 766-777.	6.0	30
150	The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends in Pharmacological Sciences, 2008, 29, 124-134.	8.7	129
151	Interactions of ciprofloxacin with DPPC and DPPG: Fluorescence anisotropy, ATR-FTIR and 31P NMR spectroscopies and conformational analysis. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2535-2543.	2.6	78
152	Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opinion on Pharmacotherapy, 2008, 9, 267-283.	1.8	37
153	Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic) Tj ETQq1 1 0.7843	31 <b>43rg</b> BT/0	Overdock 10 T
154	Restoration of Susceptibility of Methicillin-resistant Staphylococcus aureus to $\hat{I}^2$ -Lactam Antibiotics by Acidic pH. Journal of Biological Chemistry, 2008, 283, 12769-12776.	3.4	41
155	Cooperation between Prokaryotic (Lde) and Eukaryotic (MRP) Efflux Transporters in J774 Macrophages Infected with <i>Listeria monocytogenes </i> Studies with Ciprofloxacin and Moxifloxacin. Antimicrobial Agents and Chemotherapy, 2008, 52, 3040-3046.	3.2	26
156	Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. Antimicrobial Agents and Chemotherapy, 2008, 52, 2236-2238.	3.2	16
157	Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes. Journal of Antimicrobial Chemotherapy, 2008, 62, 518-521.	3.0	18
158	Restoration of Susceptibility of Intracellular Methicillin-Resistant <i>Staphylococcus aureus</i> to β-Lactams: Comparison of Strains, Cells, and Antibiotics. Antimicrobial Agents and Chemotherapy, 2008, 52, 2797-2805.	3.2	26
159	A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2007, 59, 378-386.	3.0	78
160	Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. Journal of Antimicrobial Chemotherapy, 2007, 60, 965-972.	3.0	42
161	Role of Acidic pH in the Susceptibility of Intraphagocytic Methicillin-Resistant Staphylococcus aureus Strains to Meropenem and Cloxacillin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1627-1632.	3.2	32
162	Multidrug-Resistant Streptococcus pneumoniae Infections. Drugs, 2007, 67, 2355-2382.	10.9	104

#	Article	IF	CITATIONS
163	Pseudomonas aeruginosa : résistance et options thérapeutiques à l'aube du deuxième millénaire. Antibiotiques, 2007, 9, 189-198.	0.1	3
164	Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized Staphylococcus aureus by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells. Antimicrobial Agents and Chemotherapy, 2007, 51, 2748-2757.	3.2	53
165	Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clinical Microbiology and Infection, 2007, 13, 560-578.	6.0	455
166	Passive diffusion of polymeric surfactants across lipid bilayers. Journal of Controlled Release, 2007, 120, 79-87.	9.9	24
167	Inhibitors of Bacterial Efflux Pumps as Adjuvants in Antibiotic Treatments and Diagnostic Tools for Detection of Resistance by Efflux. Recent Patents on Anti-infective Drug Discovery, 2006, 1, 157-175.	0.8	125
168	Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: Insight into the mechanism of ligand migration and binding sites. Proteins: Structure, Function and Bioinformatics, 2006, 63, 466-478.	2.6	28
169	Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2006, 58, 1177-1184.	3.0	100
170	Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK 1 Cells Subjected to Electroporation. Antimicrobial Agents and Chemotherapy, 2006, 50, 1213-1221.	3.2	73
171	Cellular Accumulation and Activity of Quinolones in Ciprofloxacin-Resistant J774 Macrophages. Antimicrobial Agents and Chemotherapy, 2006, 50, 1689-1695.	3.2	24
172	Water-soluble amphotericin B–polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. Journal of Antimicrobial Chemotherapy, 2006, 57, 236-244.	3.0	52
173	Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. Journal of Antimicrobial Chemotherapy, 2006, 59, 246-253.	3.0	87
174	Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages. Antimicrobial Agents and Chemotherapy, 2006, 50, 841-851.	3.2	228
175	Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Current Opinion in Drug Discovery & Development, 2006, 9, 218-30.	1.9	55
176	Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Current Opinion in Investigational Drugs, 2006, 7, 740-9.	2.3	34
177	Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. Chemistry and Physics of Lipids, 2005, 133, 1-15.	3.2	21
178	Quinolones in 2005: an update. Clinical Microbiology and Infection, 2005, 11, 256-280.	6.0	297
179	Gentamicin-induced apoptosis in LLC-PK1 cells: Involvement of lysosomes and mitochondria. Toxicology and Applied Pharmacology, 2005, 206, 321-333.	2.8	124
180	Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. Journal of Antimicrobial Chemotherapy, 2005, 55, 511-517.	3.0	62

#	Article	IF	CITATIONS
181	Mixed-Lipid Storage Disorder Induced in Macrophages and Fibroblasts by Oritavancin (LY333328), a New Glycopeptide Antibiotic with Exceptional Cellular Accumulation. Antimicrobial Agents and Chemotherapy, 2005, 49, 1695-1700.	3.2	32
182	Activity of three $\hat{I}^2$ -lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2005, 55, 897-904.	3.0	50
183	Accumulation and Oriented Transport of Ampicillin in Caco-2 Cells from Its Pivaloyloxymethylester Prodrug, Pivampicillin. Antimicrobial Agents and Chemotherapy, 2005, 49, 1279-1288.	3.2	19
184	Comparison of three differential media for the presumptive identification of yeasts. Clinical Microbiology and Infection, 2005, 11, 513-515.	6.0	1
185	Influence of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin,) Tj ETQq1 Chemotherapy, 2005, 49, 2429-2437.	1 0.784314 r <sub>s</sub> 3.2	gBT /Overloo 76
186	Impairment of Growth ofListeria monocytogenesin THPâ€1 Macrophages by Granulocyte Macrophage Colonyâ€6timulating Factor: Release of Tumor Necrosis Factorâ€"α and Nitric Oxide. Journal of Infectious Diseases, 2004, 189, 2101-2109.	4.0	29
187	Inhibition of TNF-Â production in THP-1 macrophages by glatiramer acetate does not alter their susceptibility to infection by Listeria monocytogenes and does not impair the efficacy of ampicillin or moxifloxacin against intracellular bacteria. Journal of Antimicrobial Chemotherapy, 2004, 54, 288-289.	3.0	1
188	Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter. Antimicrobial Agents and Chemotherapy, 2004, 48, 2673-2682.	3.2	52
189	Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages. Antimicrobial Agents and Chemotherapy, 2004, 48, 2853-2860.	3.2	66
190	Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. Toxicology and Applied Pharmacology, 2004, 194, 101-110.	2.8	17
191	Glycopeptide Antibiotics. Drugs, 2004, 64, 913-936.	10.9	181
192	Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current Opinion in Pharmacology, 2004, 4, 471-478.	3.5	96
193	Intracellular pharmacodynamics of antibiotics. Infectious Disease Clinics of North America, 2003, 17, 615-634.	5.1	164
194	Piracetam inhibits the lipid-destabilising effect of the amyloid peptide $A\hat{l}^2$ C-terminal fragment. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1609, 28-38.	2.6	13
195	Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular Staphylococcus aureus in Mouse J774 Macrophages. Antimicrobial Agents and Chemotherapy, 2003, 47, 2283-2292.	3.2	140
196	Influence of P-Glycoprotein Inhibitors on Accumulationof Macrolides in J774 MurineMacrophages. Antimicrobial Agents and Chemotherapy, 2003, 47, 1047-1051.	3.2	64
197	Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. Journal of Antimicrobial Chemotherapy, 2003, 51, 1051-1052.	3.0	40
198	Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2003, 51, 1167-1173.	3.0	101

#	Article	IF	CITATIONS
199	Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. Journal of Antimicrobial Chemotherapy, 2003, 51, 1055-1065.	3.0	162
200	Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. Journal of Antimicrobial Chemotherapy, 2003, 51, 1067-1077.	3.0	75
201	Intracellular accumulation and activity of ampicillin used as freedrug and as its phthalimidomethyl or pivaloyloxymethyl ester (pivampicillin) against Listeria monocytogenes in J774 macrophages. Journal of Antimicrobial Chemotherapy, 2003, 52, 610-615.	3.0	8
202	Comparative Intracellular (THP-1 Macrophage) and Extracellular Activities of $\hat{l}^2$ -Lactams, Azithromycin, Gentamicin, and Fluoroquinolones against <i>Listeria monocytogenes</i> Concentrations. Antimicrobial Agents and Chemotherapy, 2002, 46, 2095-2103.	3.2	116
203	Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 Macrophages. Experimental Cell Research, 2002, 281, 86-100.	2.6	76
204	Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 Macrophages. Experimental Cell Research, 2002, 281, 86-86.	2.6	6
205	Membrane destabilization induced by $\hat{l}^2$ -amyloid peptide 29-42: Importance of the amino-terminus. Chemistry and Physics of Lipids, 2002, 120, 57-74.	3.2	37
206	Macrolides: pharmacokinetics and pharmacodynamics. International Journal of Antimicrobial Agents, 2001, 18, 17-23.	2.5	83
207	Sequencing of the ddl gene and modeling of the mutated D-alanine:D-alanine ligase in glycopeptide-dependent strains of Enterococcus faecium. Protein Science, 2001, 10, 836-844.	7.6	28
208	Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts. European Journal of Cell Biology, 2001, 80, 466-478.	3.6	35
209	Experimental and Conformational Analyses of Interactions between Butenafine and Lipids. Antimicrobial Agents and Chemotherapy, 2001, 45, 3347-3354.	3.2	20
210	Antibiotic efflux pumps. Biochemical Pharmacology, 2000, 60, 457-470.	4.4	327
211	Biophysical studies and intracellular destabilization of pHâ€sensitive liposomes. Lipids, 2000, 35, 213-223.	1.7	33
212	Modeling of Enterococcus faecalis D-alanine: D-alanine ligase: structure-based study of the active site in the wild-type enzyme and in glycopeptide-dependent mutants. Journal of Molecular Microbiology and Biotechnology, 2000, 2, 321-30.	1.0	4
213	Interactions of Macrolide Antibiotics (Erythromycin A, Roxithromycin, Erythromycylamine) Tj ETQq1 1 0.784314 Studies on Acellular and Cell Culture Models. Toxicology and Applied Pharmacology, 1999, 156, 129-140.	rgBT /Ove 2.8	rlock 10 Tf <mark>50</mark> 80
214	Vancomycin-Dependent <i>Enterococcus faecalis </i> Clinical Isolates and Revertant Mutants. Antimicrobial Agents and Chemotherapy, 1999, 43, 41-47.	3.2	72
215	Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. Journal of Antimicrobial Chemotherapy, 1998, 42, 761-767.	3.0	39
216	Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. FEBS Letters, 1996, 394, 307-310.	2.8	19

#	Article	IF	CITATIONS
217	Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. European Journal of Pharmacology, 1996, 314, 203-214.	3.5	53
218	Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. European Journal of Pharmacology, 1996, 314, 215-227.	3.5	35
219	Aminoglycoside antibiotics prevent the formation of non-bilayer structures in negatively-charged membranes. Comparative studies using fusogenic (bis $(\hat{l}^2$ -diethylaminoethylether)hexestrol) and aggregating (spermine) agents. Chemistry and Physics of Lipids, 1996, 79, 123-135.	3.2	14
220	Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes. European Journal of Pharmacology, 1995, 289, 321-333.	2.6	33
221	Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells. European Journal of Pharmacology, 1993, 247, 155-168.	2.6	44
222	Dangerous Slimes: How Bacterial Biofilms Make You Sick and How to Combat Them. Frontiers for Young Minds, 0, 8, .	0.8	1